U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its ...
AbbVie’s top job today centers on developing new sources of revenue out of the fear that biosimilars to its megablockbuster Humira will cause a precipitous sales decline starting in 2023. But after ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first Humira biosimilar hit the U.S. market a little ...
No more waiting: Humira’s judgment day has finally arrived. The first Humira biosimilar, Amgen’s Amjevita, is set to reach the market Tuesday and kick off a tsunami-sized wave of competition. With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback